Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
The Californer/10361030

PHOENIX - Californer -- Sibannac, Inc. (OTC PINK: SNNC) $SNNC is advancing its wellness growth strategy with a significant announcement that introduces a new platform for potential business expansion. The company announced today that it holds a 51% majority interest in Apollo Wellness Centers, Inc., a newly formed joint venture with Doc-Rx.com, LLC. The initiative combines an established telehealth platform, relationships with partner compounding pharmacies, a U.S.-based peptide supply chain and plans to develop a network of branded wellness clinics.

For SNNC investors, this development represents an important addition to the company's business portfolio and creates a new opportunity to participate in the expanding market for medically supervised wellness services.

The strategy is particularly interesting because Apollo is designed to build upon infrastructure that Doc-Rx already operates. Rather than beginning with an entirely new technology platform, the venture intends to use existing capabilities as a foundation for developing its own branded clinic network and additional wellness offerings.

With Sibannac holding the majority interest, the company is positioning Apollo as a potential contributor to its broader growth ambitions.

A Major New Development for Sibannac Shareholders

The October 27 announcement confirms Sibannac's 51% ownership interest in Apollo Wellness Centers under a joint venture agreement dated October 1, 2026.

This majority position gives Sibannac the controlling ownership interest in the new venture, while Doc-Rx serves as its strategic partner.

Apollo's initial platform includes several complementary capabilities:

• Telehealth services: Online consultations through licensed healthcare professionals.
• Pharmacy partnerships: Relationships with partner 503A compounding pharmacies supporting prescriptions from licensed prescribers.
• U.S.-based peptide supply chain: Domestic sourcing and production capabilities described by the companies as extending from raw materials through finished products.
• Health tracking: Technology intended to support the broader wellness services offering.
• Branded clinic development: A planned network of Apollo Wellness Centers locations through a licensing model.

Together, these elements give Apollo a foundation from which to pursue a broader wellness business. The company's immediate opportunity is to organize these capabilities under one brand and develop a scalable commercial model.

Apollo Wellness Centers: A Platform Designed for Expansion

One of the most compelling elements of the announcement is Apollo's proposed clinic licensing strategy.

More on The Californer

• Couple Turn 35 Years of Rescuing Bully Breeds Into a Natural Dog Chew Brand for the US Market
• Mesa West Capital Provides $61.5 Million Loan to Finance Silicon Valley Office Property
• Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network
• Boardroom Knowledge System Leaders Have Been Waiting For: Fireflies.ai Enterprise via ISATONG
• Dynamic Relaunch as AI Predictive Cybersecurity Company Optimized to Prevent Threats Proactively: Cycurion, Inc. (N A S D A Q: CYCU)

The company expects wellness clinics operating under the Apollo Wellness Centers brand to become its largest source of revenue. Under the proposed model, licensed prescribers would own individual clinics, license the Apollo brand and order through Doc-Rx.

This approach is intended to enable the brand to expand without requiring Apollo itself to own every physical location.

For Sibannac, the model offers an opportunity to develop a broader business presence through partnerships with licensed healthcare professionals. As the network grows, Apollo could potentially benefit from increased brand recognition, participation in its supporting platform and additional commercial activity associated with its services.

The initial focus will be on translating the platform into operational clinics and establishing the relationships needed to support expansion.

Although the company has not announced a specific number of locations or a clinic-opening timetable, the licensing strategy establishes a clear direction for Apollo's development.

Doc-Rx Adds Existing Technology and Healthcare Relationships

Doc-Rx is central to the venture's strategy because it brings an operating telehealth platform and existing relationships with partner pharmacies.

The platform connects licensed clinicians with patients through online consultations, with prescriptions handled through partner pharmacies when appropriate. Its health-tracking capabilities also complement the broader concept of personalized, professionally supervised wellness.

The companies describe the peptide supply chain as U.S.-based, covering the process from domestic raw materials through synthesis and compounding.

These capabilities give Apollo a starting point for developing its branded clinic network and exploring additional services.

For investors, the combination of Sibannac's majority ownership and Doc-Rx's existing platform creates a strategic opportunity to develop a new wellness business without having to construct every component independently.

Additional Growth Opportunities in Products and Telemedicine

Apollo's ambitions extend beyond physical wellness clinics.

The joint venture also plans to develop its own product line, potentially including peptides, nutraceuticals and medical foods, alongside expanded telemedicine services.

These planned offerings could complement the clinic network and create additional opportunities for brand development over time.

A combined approach incorporating clinics, telehealth and wellness products could allow Apollo to pursue several related areas of the market through a coordinated business strategy.

For Sibannac, this creates an opportunity to broaden its participation in the wellness sector while developing another business platform alongside its existing portfolio.

Product launches expanded services and future clinic development remain important milestones to watch as the venture progresses.

More on The Californer

• Wordly Launches Audience Engagement, Turning Live Event Content into Actionable Intelligence
• EMBER™ Unveils the Workplace Identity Score™ (WIS™), the First Standard for Measuring Workplace Impact on Workforce Performance & Business Growth
• With Oil Prices Surging…Sky Quarry's Nevada Refinery Is Back in Action — CEO Highlights a Powerful New Growth Chapter for (N A S D A Q: SKYQ)
• Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year
• We are Talker Study: 64% of AI Users Have Bought From a Brand AI Introduced, as The Invisible Shortlist Reshapes Brand Discovery

Building on Sibannac's Broader Wellness Vision

Sibannac has described its strategy as building a portfolio of wellness businesses, emerging consumer brands, product-development capabilities and strategic partnerships.

Earlier in 2026, the company announced initiatives involving functional mushroom and moringa products, as well as a proposed joint venture to develop a compliant psilocybin research facility. In August, Sibannac also announced a non-binding letter of intent concerning a potential strategic collaboration and transaction focused on patient health.

Those initiatives reflect the company's interest in pursuing opportunities across several areas of wellness, research and personalized health services.

The Apollo announcement adds a distinct dimension to this strategy: a majority-owned venture focused on medically supervised wellness, telehealth and a planned clinic network.

The potential benefit is the opportunity to build a broader collection of complementary businesses rather than depend on a single product category.

What Investors Will Be Watching Next

With Apollo's strategic foundation now announced, several developments could help demonstrate its progress:

• Clinic network expansion: Updates on licensed providers, participating locations and the launch of Apollo-branded clinics.
• Commercial progress: Evidence of growing provider participation and revenue-generating activity.
• New offerings: Progress toward the planned peptide, nutraceutical and medical-food product lines.
• Telehealth development: Updates on the expansion and use of Doc-Rx's supporting platform.
• Financial contributions: Future disclosures clarifying Apollo's operating performance and the contribution of Sibannac's ownership interest.

These milestones could help investors assess how the new venture develops and how it contributes to Sibannac's overall business.

The Bottom Line: A New Chapter of Opportunity for $SNNC

Sibannac's October 27 announcement introduces an important new growth initiative through its 51% majority interest in Apollo Wellness Centers.

With access to Doc-Rx's operating telehealth platform, pharmacy relationships and U.S.-based peptide supply chain, Apollo intends to establish a branded wellness clinic network and explore additional products and services.

The opportunity lies in bringing these capabilities together under one business platform and building a model that can expand through licensed healthcare professionals.

For SNNC shareholders, Apollo represents a development worth watching as Sibannac continues to broaden its wellness portfolio and pursue new avenues for business growth.

The next milestone is execution: establishing the Apollo brand, attracting participating providers, developing clinics and translating the venture's capabilities into measurable commercial progress.

As the company moves forward, additional announcements regarding clinic development, new services and operating performance will help shape the story for investors following Sibannac.

For more information on SNNC visit: www.snncinc.com

Media Contact:

Company Name: Sibannac, Inc.

Contact Person: David Mersky

Email: investors@sibannacinc.com

Phone: (480) 407-6445
Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website